Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world

被引：0
|
作者：
Sugisaka, J. [1 ]
Sugawara, S. [1 ]
Toi, Y. [1 ]
Ogasawara, T. [1 ]
Aso, M. [1 ]
Tsurumi, K. [1 ]
Ono, K. [1 ]
Shimizu, H. [1 ]
Domeki, Y. [1 ]
Aiba, T. [1 ]
Kawana, S. [1 ]
Saito, R. [1 ]
Terayama, K. [1 ]
Kawashima, Y. [1 ]
Nakamura, A. [1 ]
Yamanda, S. [1 ]
Kimura, Y. [1 ]
Honda, Y. [1 ]
机构：
[1] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
336P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
    Dolores Isla
    Marta Lopez-Brea
    María Espinosa
    Natalia Arrabal
    Diego Pérez-Parente
    David Carcedo
    Reyes Bernabé-Caro
    Cost Effectiveness and Resource Allocation, 21
  • [32] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
    Isla, Dolores
    Lopez-Brea, Marta
    Espinosa, Maria
    Arrabal, Natalia
    Perez-Parente, Diego
    Carcedo, David
    Bernabe-Caro, Reyes
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [33] Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia
    Cheng, Ying
    Yang, James Chih-Hsin
    Okamoto, Isamu
    Zhang, Li
    Hu, Jie
    Wang, Donglin
    Hu, Chengping
    Zhou, Jianying
    Wu, Lin
    Cao, Lejie
    Liu, Jiwei
    Zhang, Helong
    Sun, Hong
    Wang, Ziping
    Gao, Hongjun
    Yan, Yan
    Xiao, Suijun
    Lin, Jianxin
    Pietanza, M. Catherine
    Kurata, Takayasu
    IMMUNOTHERAPY, 2023, 15 (13) : 1029 - 1044
  • [34] Neoadjuvant immunochemotherapy of pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
    Chen, Y.
    Yan, B.
    You, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S108 - S109
  • [35] Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
    Chen, Yulong
    Yan, Bo
    Zhang, Ran
    Zhao, Gang
    You, Jian
    HELIYON, 2023, 9 (09)
  • [36] Real-world clinical outcomes of neoadjuvant chemotherapy plus pembrolizumab or tislelizumab in resectable non-small cell lung cancer
    Hu, Yan
    Ren, Siying
    Wu, Fang
    Liu, Wenliang
    RESPIROLOGY, 2024, 29 : 41 - 41
  • [37] Advanced non-small cell lung cancer - treatment with Pembrolizumab
    Silvinato, Antonio
    Floriano, Idevaldo
    Bernardo, Wanderley Marques
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (03): : 256 - 256
  • [38] Advanced non-small cell lung cancer - Treatment with Pembrolizumab
    Silvinato, Antonio
    Floriono, Idevaldo
    Bernardo, Wanderley Marques
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2019, 65 (12): : 1423 - 1432
  • [39] Profiling of immune related adverse events from nivolumab or pembrolizumab monotherapy in advanced non-small cell lung cancer in real world
    Aso, M.
    Sugawara, S.
    Toi, Y.
    Sugisaka, J.
    Ono, H.
    Tsurumi, K.
    Suzuki, K.
    Shimizu, H.
    Domeki, Y.
    Aiba, T.
    Kawana, S.
    Saito, R.
    Terayama, K.
    Kawashima, Y.
    Nakamura, A.
    Yamanda, S.
    Kimura, Y.
    Honda, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study
    Qiang, Huiping
    Lei, Yuqiong
    Shen, Yinchen
    Li, Jiaqi
    Zhong, Hua
    Zhong, Runbo
    Zhang, Xueyan
    Chang, Qing
    Lu, Jiahuan
    Feng, Hui
    Zhu, Yan
    Addeo, Alfredo
    Banna, Giuseppe L.
    Oh, In-Jae
    Qian, Jialin
    Chu, Tianqing
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (01) : 87 - 99
12345